We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+119.85%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$242M
AUM Growth
+$88.7M
Cap. Flow
-$51.4M
Cap. Flow %
-21.19%
Top 10 Hldgs %
63.25%
Holding
38
New
12
Increased
4
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$16.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14M
3
APGE icon
Apogee Therapeutics
APGE
+$11.6M
4
NKTR icon
Nektar Therapeutics
NKTR
+$9.93M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$6.79M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$70M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$20.5M
3
LEGN icon
Legend Biotech
LEGN
+$8.73M
4
AKBA icon
Akebia Therapeutics
AKBA
+$7.23M
5
EOLS icon
Evolus
EOLS
+$6.63M

Sector Composition

Rank Sector Weight
1 Healthcare 98.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SANA icon
26
Sana Biotechnology
SANA
$885M
$2.48M 1.02%
+700,000
New +$2.53M
ABSI icon
27
Absci
ABSI
$1.28B
$2.42M 1%
+796,438
New +$2.2M
HRMY icon
28
CALL
Harmony Biosciences
HRMY
$2.04B
$2.34M 0.97%
+85,000
New +$2.93M
PLRX icon
29
Pliant Therapeutics
PLRX
$67.5M
$1.26M 0.52%
850,000
– –
CAPR icon
30
PUT
Capricor Therapeutics
CAPR
$1.14B
$632K 0.26%
+87,700
New +$646K
ACLX
31
DELISTED
Arcellx
ACLX
– –
-100,000
Closed -$6.58M
AKBA icon
32
Akebia Therapeutics
AKBA
$327M
– –
-1,985,915
Closed -$7.23M
CNTA
33
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-225,000
Closed -$2.96M
EOLS icon
34
Evolus
EOLS
$394M
– –
-720,118
Closed -$6.63M
KALV
35
DELISTED
KalVista Pharmaceuticals
KALV
– –
-323,170
Closed -$3.65M
PMN icon
36
ProMIS Neurosciences
PMN
$109M
– –
-105,805
Closed -$1.28M
SRRK icon
37
Scholar Rock
SRRK
$5.71B
– –
-61,607
Closed -$2.18M
BBOT
38
BridgeBio Oncology
BBOT
$707M
– –
-29,381
Closed -$312K
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
NF
Napier Financial Braintree, Massachusetts $436M AUM
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Great Point Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Great Point Partners held 38 positions worth $242M, up 58% from $154M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Great Point Partners withdrew a net $51.4M in Q3 2025, closing 8 positions and reducing 6 holdings. Its most notable exit was Akebia Therapeutics, an estimated $7.23M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Soleno Therapeutics worth $15.2M.

  • Great Point Partners's largest Q3 2025 buy was Soleno Therapeutics: 225,000 shares worth $15.2M.
  • Great Point Partners added most to Immunovant in Q3 2025, an estimated $3.85M increase.
  • Great Point Partners's biggest Q3 2025 reduction was Abivax, cutting an estimated $70M.
  • Great Point Partners fully exited Akebia Therapeutics in Q3 2025, selling an estimated $7.23M.
  • Great Point Partners's ten largest holdings make up 63% of its $242M portfolio in Q3 2025.
  • Great Point Partners opened 12 new positions and closed 8 in Q3 2025.
  • Great Point Partners's portfolio value rose 58% quarter-over-quarter to $242M.

Based on Great Point Partners's 13F filing for Q3 2025, filed 14 Nov 2025.